Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
July 02, 2024 16:05 ET
|
Avid Bioservices, Inc
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and...
Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual Meeting
July 02, 2024 08:00 ET
|
Bionano Genomics
A sponsored session will feature Dr. Lucia Gallego Villarejo from Ruhr University Bochum, Dr. Jeanne Loring from Scripps Research Institute, and Dr. Alicia Bertolotti from Bionano presenting on the...
Gene Therapy R&D Market Report 2024-2034 - Gene Therapy Resurgence Fuelled by Groundbreaking Advancements, Soaring Investments and a Promising Pipeline Reshaping Medicine's Future
July 01, 2024 10:10 ET
|
Research and Markets
Dublin, July 01, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy R&D Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering. World revenue for Gene Therapy R&D Market is...
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
July 01, 2024 07:00 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market Research 2023-2031: Stringent Regulatory Requirements, Growing Adoption of Personalized Medicine, Competition to Intensify
June 27, 2024 06:23 ET
|
Research and Markets
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key...
Global Cell and Gene Therapy CRO Market Research 2024-2035: Over 105 CROs Drive Innovations with 80% Ensuring Comprehensive Support from R&D to Clinical Trials
June 26, 2024 06:37 ET
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification,...
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
June 21, 2024 07:00 ET
|
Ocugen
• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial• DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) --...
Adeno-associated Virus Gene Therapy Market Report 2024-2034: Epidemiology, Industry Trends and Forecasts
June 21, 2024 06:05 ET
|
Research and Markets
Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "Adeno-associated Virus Gene Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been...
CRISPR and Cas Genes Market Research 2024 - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F
June 20, 2024 07:24 ET
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "CRISPR and Cas Genes Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F" report has been added to ...
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
June 20, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...